February 7, 2017

Titans of Industry: The Frazier v. Ali of Patent Litigation

February 7, 2017

The Role of Patents in the Fight Against Superbugs: Are Patent Laws Discouraging Investment in Promising Superbug Treatments?

February 7, 2017

The Biologics Price Competition and Innovation Act: Commercial Marketing in the Spotlight

March 31, 2016

Antitrust Issues in Reverse Payment Settlements: A Case Study

March 31, 2016

Awarding Enhanced Damages in Patent Infringement Cases

March 31, 2016

Deference Runs Deep: The Ill Effects of Alice

February 21, 2016

Data Exclusivity for Biologic Drugs: the TPP’s Potential Poison Pill?

February 9, 2016

Federal Circuit reviews the $1.5 billion judgment against Marvell

February 9, 2016

“Cross-checking” as a Claim Construction Strategy

February 9, 2016

A Review of the Modern IPR Process

February 9, 2016

The CRISPR Patent Battle: Who Will be “Cut” Out of Patent Rights to One of the Greatest Scientific Discoveries of Our Generation?

November 25, 2015

Intersection of American Law and Technology: The Innovation Act’s Fight Against Patent Trolls

November 25, 2015

Daraprim and the Pharmaceutical Pricing Paradox: A Broken System?

May 6, 2015

McRO v. Activision Blizzard: Software Patents in a Post-Alice World

May 1, 2015

Patent Reissue: Uses and Strategy (Part III)

April 29, 2015

Patent Reissue: Uses and Strategy (Part II)

April 27, 2015

Patent Reissue: Uses and Strategy (Part I)

March 18, 2015

Teva Pharm. USA, Inc. v. Sandoz, Inc.

December 27, 2013

Association for Molecular Pathology v. Myriad Genetics

November 10, 2013

The Patent Bar: What it is and What it Means For You

November 5, 2013

Bowman v Monsanto Replicates Problems for the Future

April 23, 2013

Intellectual Property Indemnity Clauses

October 24, 2012

Do Business Method Patents Encourage Innovation?

June 11, 2012

Dosage Patenting in Personalized Medicine

September 22, 2010

Patent Litigation: What About Qualification Standards for Court Appointed Experts?

September 22, 2010

Proveris v. Innovasystems: Redefining a Patented Invention under § 271(E)(1): An Examination of the Federal Circuit's Narrowing of the § 271(e)(1) “Safe Harbor” Exemption

July 19, 2009

The Biologics Price Competition and Innovation Act: Innovation Must Come Before Price Competition

July 5, 2009

Rounding Up Plant Patents & Other Growing Patent Concerns a Comment on Monsanto v. Schmeiser

January 21, 2009

Can An Internet Reference Be A "Printed Publication"?

January 1, 2009

Utility Models and Their Comparison with Patents and Implications For The US Intellectual Property Law System

November 1, 2008

Shopping for Expedient, Inexpensive & Predictable Patent Litigation

March 26, 2008

Inequitable Results in Transnational Patent Infringement Liability: Closing The Method Loophole

November 29, 2007

Was The FDA Exemption To Patent Infringement, 35 U.S.C. § 271(e)(1), Intended To Exempt A PHarmaceutical Manufacturer's Activities In The Development Of New Drugs?

November 7, 2006

Remembering The Public's Interest In The Patent System - A Post-Grant Opposition Designed To Benefit The Public

September 30, 2005

Repairing The Bayh-Dole Act: A Proposal For Restoring Non-Profit Access To University Science

June 8, 2004

The Disruption Of The U.S. Constitutional Symmetry Of Intellectual Property To Gain Conformity With An International Property Framework: A Road To A Global Market Or A Tripping Point To The Gradual Collapse Of The U.S. Economy?

October 31, 2003

Foreseeability As A Bar To The Doctrine Of Equivalents